Pharmaceutical

Sentynl acquires Eiger’s Zokinvy for progeria treatment

Sentynl Therapeutics has announced the acquisition of Zokinvy programme from Eiger BioPharmaceuticals for the treatment of progeria.

May 7, 2024 - 00:00
Sentynl acquires Eiger’s Zokinvy for progeria treatment
Sentynl Therapeutics has announced the acquisition of Zokinvy programme from Eiger BioPharmaceuticals for the treatment of progeria.
Read the original article

Tags:

Previous Article

UK MHRA approves ViiV Healthcare’s cabotegravir formulations for HIV-1

Next Article

Amgen reports a 22% increase in Q1 2024 net revenues

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Listen: Legal insider trading, booming biotech stocks, & the next GLP-1

Listen: Legal insider trading, booming biotech stocks, ...

Feb 29, 2024

Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

Johnson & Johnson agrees to acquire Ambrx Biopharma for...

Jan 9, 2024

Pharmanovia signs licence deal for Aeterna Zentaris’ Ghryvelin

Pharmanovia signs licence deal for Aeterna Zentaris’ Gh...

Mar 19, 2023